MAP Pharmaceuticals Inc. (MAPP) leaped higher on Tuesday, following the announcement that its first Phase 3 clinical trial of LEVADEX met all four primary endpoints. The stock added to those gains Wednesday and closed at a 3 1/2 month high.
Deutsche Securities upgraded its rating on shares of MAP Pharmaceuticals Wednesday morning from a "Hold" to a "Buy." The stock gapped up at the open and climbed throughout the middle portion of the session. MAP Pharmaceuticals closed higher by $3.15 at $12.15 on the highest volume of the year.
For comments and feedback: editorial@rttnews.com